



## MITHRA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF AN ESTETROL DEVELOPMENT PROGRAMS DIRECTOR

**Liège, Belgium 16 February 2016** – Mithra Pharmaceuticals announced today the appointment of a high level R&D profile, Bernard Cornet, to the newly created position of **Estetrol Development Programs Director**, effective on 15 February 2016. This appointment fits into the reinforcing and structuring program regarding the R&D team for Mithra’s future.

Bernard Cornet has more than 20 years of extensive experience in project management, process improvement and team leadership within multinational biopharmaceutical R&D organizations such as Sanofi, GSK or Celyad. He developed proven skills around people and organizational leadership of large group (up to 300+ people) across multiple countries and cultures and essentially in R&D laboratories and clinical development operations.

In the role of Estetrol Development Programs Director, Bernard Cornet will be responsible for the whole development of Mithra’s Estetrol-based product candidates: Estelle® (combined oral contraceptive) for contraception and Donesta® (hormone replacement therapy) for menopause, respectively ready for Phase III and Phase II.

François Fornieri, CEO of Mithra Pharmaceuticals said: “As a biopharmaceutical company, the R&D and innovation pillar underlying Mithra’s business strategy is significant. We have high hopes for our Estetrol-based projects under development. Mithra is extremely pleased to strengthen its expertise with a high-level profile like Bernard, ensuring an effective work together with the Scientific Committee, the CSO, the clinical research and the projects development.”

Mithra’s R&D team reinforcement and growth is to be continued by at least another appointment in the next few weeks, giving structure and support to the existing teams overseen by Mithra’s Chief Scientific Officer, Valérie Gordenne, as well as the Scientific Committee composed by Herjan Coelingh Bennink and Pr. Jean-Michel Foidart.

### Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/logo-et-charte-graphique/>

### For more information, please contact:

#### Press

#### Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75  
[press@mithra.com](mailto:press@mithra.com)

### **Investor Relations**

**François Fornieri, CEO**  
+32 4 349 28 22  
[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

### **About Mithra**

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

### **Important information**

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](http://investors.mithra.com)